drugset / Trial / NCT01487902
The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the androgen deprivation therapy when patients with castration-resistant prostate cancer are treated with docetaxel-based chemotherapy.
Timeline
- Start
- 2010-07
- Primary completion
- 2013-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luprolide | Unknown | 11.25 mg | Subcutaneous |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Prednisolone | Other / unclassified | — | — |